Abstract 5350
Background
Pembrolizumab (Pem) for NSCLC and PD-L1 TPS ≥50% as a first-line therapy showed the longer PFS and OS compared with chemotherapy in some clinical trial. However, only limited patients in good general condition without organ failure can participate in them and their outcomes may not be entirely representative of real-world setting.
Methods
We conducted a multicenter retrospective study across 11 medical centers (Hanshin Oncology clinical Problem Evaluation group (HOPE)). We analyzed clinical data from NSCLC patients receiving Pem as a first-line therapy between February 1st 2017 and April 30th 2018. We aimed to evaluate the efficacy and safety and to identify which patients will become more suitable candidates for Pem monotherapy.
Results
213 patients were enrolled in this study. The median age was 71 years. Out of 213 patients, 176 (82.6%) were male, 20 (9.4%) were never smokers (Median brinkman index: 900), 172 (80.8%) had ECOG PS of 0-1, 55 (25.8%) had SQ, and PD-L1 TPS were 50-74%: 97 (45.5%), 75-89%: 55 (22.1%), and 90-100%: 69 (32.4%). 39 (18.3%) of all had AEs of grades ≥3. The most frequently severe AEs was pneumonitis (10 (4.7%) including in 1 grade 4), and no patient died of severe AEs. The overall RR/DCR were 51.2%/73.2%, the median PFS/OS was 8.3/18.4 months (M). In the univariate analysis, the ECOG PS (0-1 vs. ≥2: 9.0 vs. 4.0 M, HR: 2.11, p = 0.00061), CRP/ALB (<0.3 vs. ≥0.3: NA vs. 5.9 M, HR: 1.88, p = 0.00148), and steroid usage (not usage vs. usage: 8.7 vs. 2.0 M, HR: 3.17, p = 0.00034) were significantly correlated with PFS of Pem. In the multivariate analysis, ECOG PS (0-1 vs. ≥2: HR: 1.69, p = 0.03138), CRP/ALB (<0.3 vs. ≥0.3: HR: 1.92, p = 0.00153), steroid usage (not usage vs. usage: HR: 2.94, p = 0.00267), and PD-L1 TPS (50-89% vs. 90-100%: HR: 0.65, p = 0.04984) were significantly and independently correlated with PFS of Pem.
Conclusions
Our results was consistent with the efficacy and safety of previous key clinical trials, although our study had various backgrounds. Furthermore, poor PS, high inflammatory state (CRP/ALB≥0.3), and steroid usage at the time of Pem treatment commencement were independently correlated with a shorter PFS of Pem. On the other hands, higher PD-L1 TPS (90-100%) was independently correlated with a longer PFS of Pem.
Clinical trial identification
UMIN (University Hospital Medical Information Network in Japan; number 000032470).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Tamiya: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Pharmaceutical. A. Tamiya: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Pharmaceutical. Y. Taniguchi: Speaker Bureau / Expert testimony: MSD. T. Yokoyama: Speaker Bureau / Expert testimony: Taiho Phermaceutical. K. Hirano: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Phermaceutical. T. Hirashima: Speaker Bureau / Expert testimony: Taiho Phermaceutical. M. Kanazu: Speaker Bureau / Expert testimony: MSD. T. Kumagai: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Phermaceutical. D. Fujimoto: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Phermaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
860 - Dose differential modulation of the autophagic behavior of estrogen expressing breast carcinoma cells
Presenter: Mariam Fouad
Session: Poster Display session 1
Resources:
Abstract
2304 - Synthetic peptide of tumor–associated antigen L6 formulated with polymer-based adjuvant enhances anti-tumor effects in mice
Presenter: Shih-jen Liu
Session: Poster Display session 1
Resources:
Abstract
4419 - Improving detection level of somatic mosaicism in neurofibromatosis type 1
Presenter: Kristina Karandasheva
Session: Poster Display session 1
Resources:
Abstract
5283 - Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship of ABN401, a highly selective Met inhibitor, in gastric and non-small-cell lung cancer models
Presenter: JooSeok Kim
Session: Poster Display session 1
Resources:
Abstract
5488 - Transcription factors of Snail family in the regulation of resistance of breast cancer cells to hypoxic conditions
Presenter: Alvina Khamidullina
Session: Poster Display session 1
Resources:
Abstract
5417 - Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumour cells
Presenter: Liliana Mendonça
Session: Poster Display session 1
Resources:
Abstract
5494 - Identification of novel and known FGFR gene fusions in Chinese non-small cell lung cancer
Presenter: Weixin Zhao
Session: Poster Display session 1
Resources:
Abstract
3412 - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients.
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 1
Resources:
Abstract
1815 - Leukocytosis as a negative prognostic factor in patients with lung cancer: Which subpopulation of leukocytes is responsible?
Presenter: Filip Kohutek
Session: Poster Display session 1
Resources:
Abstract
5022 - Identification of MET gene amplifications using next-generation sequencing in non-small cell lung cancer patients
Presenter: Sergi Clavé
Session: Poster Display session 1
Resources:
Abstract